BENGALURU: Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra®, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.

Wegovy® (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy® experienced weight loss of over 20%.2 Poviztra® is a second brand of Wegovy®.

This partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviz-tra®, semaglutide injection 2.4 mg, in India.

Commenting on the partnership, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, said, “Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy® in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment. This partnership brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s robust marketing and distribution capabilities to improve access to obesity treatment for people living with overweight or obesity in India.”

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, said, “We are thrilled to partner with Novo Nordisk India to bring Poviztra® to India and are proud to be the first Indian pharmaceutical company to bring the world’s most widely used and trusted GLP-1-based weight loss molecule to the Indian market. We believe in the potential of semaglutide.

With our strong understanding of the country’s diverse geographical landscape and established marketing capabilities, we are confident about making this molecule available to patients who need it the most.”

Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has strong clinical data and has been intensively studied across multiple obesity trials in the STEP and SELECT programmes.

Semaglutide as a molecule has been on the market for close to a decade, has 38 million patient-years* of exposure, and is supported by robust real-world evidence.1-4

*Number of people who have used semaglutide multiplied by the time on the medicine

The post Novo Nordisk India Collaborates with Emcure Pharma to Introduce Poviztra® as a New Option for Wegovy® appeared first on NRI News.

MUMBAI: SCHOTT Pharma, a pioneer in drug containment and delivery solutions, announced today that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture, SCHOTT Poonawalla, from Serum Institute of India (SII).  SCHOTT Poonawalla is a joint venture of SCHOTT Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in the company.

With deep healthcare investing experience and local expertise in India, having TPG join the partnership alongside SCHOTT Pharma and Serum Institute of India represents a significant milestone in SCHOTT Poonawalla’s growth, equipping the company with additional resources and strategic insight to support its long-term global ambitions.

SCHOTT Poonawalla designs advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers. The company’s portfolio features a large range of products, including cartridges for auto-injector pens, prefillable syringes for a wide variety of biologics, vials, ampoules, as well as regulatory services for biotech and pharmaceutical companies, and Contract Development and Manufacturing Organizations (CDMOs).  

“We are excited to partner with SCHOTT Pharma and Serum Institute of India and build upon SCHOTT Poonawalla’s market leadership position as India’s largest injectables-focused drug containment solutions company,” said Bhushan Bopardikar, Business Unit Partner at TPG Growth. “On the back of a world-class manufacturing infrastructure in India, SCHOTT Poonawalla has developed an industry-leading reputation by offering a comprehensive product portfolio of the highest quality for over two decades. We look forward to partnering with the senior leadership team as they continue to innovate and improve the quality and standards of pharmaceutical drug containment solutions.”

“Partnering with TPG marks an important step for us,” said Adar Poonawalla, CEO of Serum Institute of India. “Their experience in healthcare investing and global network makes them a strong partner as we scale and explore new opportunities. Our collaboration with SCHOTT Pharma will continue, ensuring supply chain resilience and advancing innovation in vaccine packaging and delivery.”

“India continues to be one of the most dynamic and strategically important manufacturing hubs for SCHOTT Pharma. Welcoming TPG to the partnership marks an exciting step forward in our collaboration. SCHOTT Pharma’s innovation capabilities and pure-play focus on injectables will be complemented by TPG’s local market expertise, relationships, and experience from its strong presence in the Indian healthcare sector. As we continue to expand our local production capacities and leading role in the Indian market, we are confident that this step will further enhance our global footprint and deliver exceptional value to our customers,” said Andreas Reisse, CEO at SCHOTT Pharma.

“Now more than ever, our pharmaceutical customers are relying on us to supply next-generation cutting-edge drug delivery solutions, as they continue to innovate, expand operations, and supply complex drugs,” said Ashok Saxena, Managing Director, SCHOTT Poonawalla. “We are excited to welcome TPG onboard as an investor, and are confident that their proven track record of successfully driving healthcare businesses in the Indian market will greatly benefit SCHOTT Poonawalla.”

The transaction is subject to customary closing conditions and is expected to close within the first half of 2025.

Jefferies acted as the financial advisor to TPG. AZB & Partners acted as the legal advisors to TPG and SCHOTT Pharma. J. Sagar Associates (JSA) acted as the legal advisors to Serum Institute.

The post SCHOTT Pharma and Serum Institute of India Announce New Partnership in Joint Venture with TPG Investment appeared first on NRI News.

Under the APA, Tillomed will acquire Manx’s product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties), and the relevant stocks for around £ 19.7 mn (including £ 4.7mn for inventory) of which £ 6.2 mn will be upfront and rest as milestone payments over the next 18 months. The deal marks a strategic milestone for Tillomed and will strengthen the company’s product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients.

Commenting on the development, Ajit Srimal, CEO of Tillomed said, “Through the acquisition of Manx’s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.”

The post Tillomed, Emcure’s European Subsidiary, Acquires Key Pharma Portfolio from Manx appeared first on NRI News.

MUMBAI: USV Pvt Ltd, recently launched Q-rite tablets, containing 200 milligrams (mg) of Quinidine Sulphate for patients with rare irregular heartbeat conditions.  This launch marks the much-needed commercial availability of Quinidine Sulphate tablets in India. This milestone underscores USV’s commitment to advancing quality patient care as a reliable healthcare partner.

India faces one of the highest burdens of cardiovascular diseases (CVD) globally. Approximately 40% of cardiac patients show signs of heart rhythm disorders, with a concerning 22% at increased risk of sudden cardiac arrest due to arrhythmia. Alarmingly, most of these patients are under the age of 40. Keeping this overlooked demographic in mind, USV took the step to commercially launch Q rite tablets in India, to improve patient outcomes.

Prashant Tewari, Managing Director, USV “We have been empathetic to the needs of patients especially individuals with cardiac conditions, and do not have an option for its management, the launch of Q rite tablets in India underscores our vision of enhancing accessibility. Our commitment to niche medication will offer targeted solutions that significantly improve patient outcomes.”

Elaborating on the importance of the launch, Dr. Aditya Kapoor, President of the Indian Society of Electrocardiology (ISE), and Dr. Ketan Mehta, Honorary General-Secretary (ISE) mentioned in a joint statement that “Quinidine being an old yet versatile multipurpose antiarrhythmic drug, its availability in India shall adequately address the need of a select group of patient population.”

Q rite tablets is currently available at pharmacies in select hospitals and through online pharmaceutical retailer Tata 1mg.

The post USV Launches Quinidine Sulphate Tablets for Rare Arrhythmia appeared first on NRI News.

With a strong presence in over 70 countries, Emcure Pharmaceuticals has been a trusted name in the pharmaceutical industry, consistently focusing on improving lives through innovative and quality pharmaceutical solutions. Sunsure will supply this power from its 150 MWp DC solar plant in Solapur, Maharashtra. This new agreement will further strengthen Emcure’s commitment to integrating sustainability across operations in its plants to minimize environmental impact.

Commenting on the PPA agreement, Sunil Mehta, Whole-time Director of Emcure Pharmaceuticals Ltd., said: “At Emcure, we are dedicated not only to improving lives through innovation and research for our differentiated portfolio but also through efficient and environment-friendly manufacturing processes. Our partnership with Sunsure Energy is a testament to promoting innovative solutions in the pharmaceutical industry to reduce the industry’s carbon footprint by embracing the power of renewable energy. Emcure is proud to be leading the adoption of solar power in the pharmaceutical industry in India.

Shashank Sharma, Founder and CEO of Sunsure Energy, commented: “We are thrilled to onboard Emcure Pharmaceuticals, a global leader in the pharmaceutical industry, to our esteemed family of customers. This PPA demonstrates Sunsure’s dedication to facilitating the renewable energy transition for leading corporations in the pharmaceutical sector. By working together, we are not only powering Emcure’s facilities with clean energy but also driving broader environmental stewardship within the industry.“

Emcure Pharmaceuticals has always been deeply committed to environmental sustainability, integrating green initiatives and eco-friendly practices across all operations. Besides adhering to current good manufacturing practices (cGMP) and international regulatory standards, Emcure’s facilities have energy-efficient equipment, follow advanced waste management and pollution control systems, and undertake rainwater harvesting. True to its philosophy of reducing, reusing, and recycling, Emcure’s R&D team has been exploring measures for solvent recycling and recovery for reuse. In addition, Emcure’s 13 manufacturing plants are equipped to ensure Zero Liquid Discharge systems and Effluent Treatment Plants along with ensuring the treatment of 100% of waste generated. These measures reflect Emcure Pharmaceutical’s dedication to protecting the environment and promoting sustainable development.

The post Emcure Pharmaceuticals Signs PPA With Sunsure Energy To Drive Energy Conservation appeared first on NRI News.

This 3-day exhibition is organized by Exhivision Media, the expo is a premier event in the burgeoning Indian pharma and laboratory equipment market, which is driven by strategic investments in healthcare and advanced R&D infrastructure. The 2024 edition of the Pune Pharma and Lab Expo will provide a dynamic platform for B2B meetings, product displays, and introductions to the latest market innovations aimed at professionals from the pharma, biotech, and healthcare industries.

According to a recent market report, the Laboratory Equipment Services Market is expected to reach $22.1 billion by 2027, growing at a CAGR of 11.1%. This growth is fueled by the increasing need for precise diagnostics, reduced operational downtime, and cost-effective solutions meeting stringent quality standards, with the Asia-Pacific region leading this expansion.

“We are excited to bring the Pune Pharma and Lab Expo back to Pune, which has become a key hub for pharmaceutical innovation and technology,” said Ajeetkumar Shukla, Director of Exhivision Media. “This event not only highlights the latest advancements in our industry but also provides a crucial platform for forging robust business relationships across India and beyond.”

The Expo will feature state-of-the-art exhibits in pharmaceutical machinery, lab and analytical instruments, and a vast array of other products critical to the pharmaceutical and healthcare sectors. The event anticipates over 5,000 visitors, including senior pharma executives, QA/QC managers, R&D professionals, and procurement managers from around the world, offering them unparalleled access to the latest technologies and market trends.

In FY23, the Indian pharma market witnessed a remarkable year-on-year growth of nearly 5%, reaching $49.78 billion. Notably, exports grew modestly by 3%, while the domestic market surged by 7% year-on-year. Developed markets recorded an 8% growth, overcoming challenges posed by the Russia-Ukraine conflict, scarcity of foreign currency in several African countries, and significant depreciation of local currencies in emerging markets.

The post Pune Pharma And Lab Expo To Showcase New Technologies Bolstering Nationwide and Global Business Ties appeared first on NRI News.

This green field project will expand the manufacturing capabilities of SAVA Healthcare Limited as well as contribute to the development of the local economy by creating 1000+ job opportunities and offering advanced skill development for the locals.

Speaking about the new manufacturing plant, Vinod Jadhav, Chairman, of SAVA Healthcare Limited, said: “We are thrilled to commence this facility as it marks the initiation of a transformative phase in our journey. We want to emerge as a key player in the global contract manufacturing landscape and by expanding our manufacturing capabilities, we not only achieve that but also elevate Indore’s position in the pharmaceutical landscape.”

Nestled strategically on 13.8 acres of prime land, the forthcoming facility will boast of modern infrastructure and technologies designed to meet the stringent regulatory standards such as EuGMP / USFDA of global pharmaceutical markets, especially Europe and the United States of America.

The construction of the facility is slated to be executed in two planned phases. The first phase with a built-up area of 29,000 square meters is targeted for completion within 12 months, while the second phase will be completed by 2026.

“The new manufacturing facility will cater to the growing demand for quality pharmaceuticals in India and globally. Through this expansion, we will additionally create meaningful opportunities for the people in the region,” said Dinesh Kapoor, Managing Director, SAVA Healthcare Limited.

The new manufacturing plant in Indore will boost the manufacturing capability of SAVA Healthcare, which already operates a Health Canada, PIC/s approved facility in Gujarat’s Surendranagar. The proposed plant will have a projected annual production capacity of 2,351.3 million stock-keeping units which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays, and dry powders for inhalation.

In the past decade, SAVA Healthcare’s business vertical catering to animal healthcare, SAVAVET, has emerged as a leader in the small animal pharmaceutical business, and growing CMO/ CDMO business with leading Pharma companies in the Indian and overseas market.
SAVA Healthcare is a trusted manufacturing partner to top Indian pharmaceutical companies and has a global footprint with exports of pharmaceutical products to more than 35 countries including Canada, Ukraine, the CIS, Asia, and Africa (especially FWA – French West Africa).

The post SAVA Healthcare’s New Manufacturing Plant In Indore Set To Boost Employment Opportunities In The Region appeared first on NRI News.

MUMBAI: India’s leading Pharma Company in the oral healthcare segment – ICPA Health Products Ltd (ICPA) welcomes world-renowned periodontal expert – Professor Giovanni Zucchelli to India for his inaugural visit, marking a significant milestone in advancing dental education and innovation in periodontal and peri-implant soft tissue corrective surgeries in the country. In an exclusive interview with ICPA, the ace surgeon shares his journey in dentistry, his achievements, key lessons he learned from life and the profession; and his vision for dentistry especially, periodontics. The world-renowned innovator in periodontal plastic surgeries and mucogingival aesthetic surgeries around implants will host a master class for aspiring dentists in Delhi on the 17^th and 18^th of this month.

Prof Giovanni Zucchelli, DDS, Ph.D., is the Professor of Periodontology and Implantology at the University of Bologna, Italy. He has received numerous awards for his clinical research in periodontology in both Europe and the United States. Prof Zucchelli has authored over 100 Pubmed-indexed publications and is the author of two bestselling books ‘Mucogingival Esthetic Surgery’ and ‘Mucogingival Esthetic Surgery Around Implants.’ Additionally, he has co-authored two illustrated textbooks on periodontal plastic surgery and contributed a chapter on ‘Mucogingival Therapy-Periodontal Plastic Surgery’ in Jan Lindhe’s textbook ‘Clinical Periodontology and Implant Dentistry’.

To watch the interview click on the link below which also includes an event link to register for the master class at the end:

The post ICPA Welcomes Global Leader In Periodontal Aesthetics – Prof Giovanni Zucchelli On His Inaugural Visit To India appeared first on NRI News.

The heartwarming new television commercial features Ranbir Kapoor engaging in a friendly sibling rivalry with the family pet, a lovable dog named Rocko. The narrative revolves around a race to the dining table, with Neetu Kapoor calling them both for breakfast. The endearing portrayal of this relationship highlights the genuine bond shared between family members, including pets, and reinforces PetStar’s commitment to promoting a happy and healthy life for pets.

Commenting on the collaboration, Mr. Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, expressed, “We are thrilled to welcome Ranbir Kapoor and Neetu Kapoor into the PetStar family. Their warmth, relatability, and genuine love for pets align seamlessly with our brand ethos. We believe their association will not only elevate the brand’s visibility but also resonate with pet lovers across the nation.”

Mankind’s PetStar is a modern-age pet food brand designed to make pets healthy and happy. The brand’s team of veterinary nutritionists has researched for years towards crafting a range of innovative and customized recipes for pets to thrive in the Indian climate. PetStar uses only the choicest natural ingredients from the valley of Wales and special Ayurvedic herbs like Ashwagandha and Silybum marinum to nourish, protect and energize pets.

Mankind Pharma is one of the largest pharmaceutical companies in India, which focuses on the domestic market with its Pan India presence. The company operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing international quality products at affordable prices.

In conclusion, the collaboration between PetStar and the Kapoor family marks a significant milestone in the brand’s journey towards promoting a culture of care and companionship for pets. The heartwarming television commercial featuring Ranbir Kapoor and Neetu Kapoor highlights the genuine bond shared between family members, including pets, and reinforces PetStar’s commitment to promoting a happy and healthy life for pets.

The post Mankind Pharma’s PetStar Ties Up with Ranbir Kapoor and Neetu Kapoor for New Campaign appeared first on NRI News.

During the World Heart Month Campaign, Mankind Pharma has undertaken a series of impactful activities to educate and empower individuals to take control of their heart health. The pharma giant is encouraging healthcare professionals to take a pledge to support cardiac care awareness. They will pledge to promote heart health awareness and encourage heart-healthy lifestyles. Upon the successful completion of this pledge, participants will receive a Digital Record Certificate as a token of appreciation and recognition for their commitment to cardiac care.

As a part of the initiative, Mankind Pharma is organizing over 4000 Free Blood Pressure Camps across India which will provide easy access to blood pressure monitoring and guidance on maintaining healthy blood pressure levels. They have also collaborated with 10,000+ healthcare providers to educate patients through personalized video messages to spread awareness. Additionally, Mankind Pharma has also collaborated with The European Association for the Study of Diabetes, to help train and certify 11,622 primary healthcare centers to diagnose and manage Diabetes, Blood Pressure, and Hypertension.

The pharma brand is also hosting a public awareness webinar on tips and tricks to manage heart disease and emergency care. The webinar will be conducted in regional languages (Hindi, Odiya, Bengali, Marathi, Malayalam, Kannada, Tamil, and Telugu) to reach a wider audience. This extensive initiative aims to reach communities far and wide, making heart health assessment and guidance accessible to all.

Commenting on the campaign, Rajeev Juneja, Vice Chairman and Managing Director, of Mankind Pharma Ltd. said, “Mankind Pharma is committed to improving heart health through awareness, education, and timely intervention. Our World Heart Month Campaign 2023 reaffirms our dedication to empowering individuals with the knowledge and tools they need to take charge of their heart health. We believe that a healthy heart is the foundation of a vibrant life, and we’re committed to making a difference, one heartbeat at a time.“

Mankind Pharma is committed to promoting heart health awareness and fostering a culture of preventive healthcare. The World Heart Month Campaign 2023 represents a significant step toward achieving this goal.

Mankind has a consistent track record of product innovation, as of December 31,2022, Company had a team of over 600 scientists and dedicated in-house R&D centers with six units located in in Haryana, Maharashtra, Himachal Pradesh and Uttarakhand.

The post Mankind Pharma Launches World Heart Month Campaign to Raise Awareness of Cardiac Care appeared first on NRI News.